ERBB2 and neoplasm: Previously, our group assessed the heterogeneity of Her2/neu expression and the vasculature within the tumor microenvironment (TME) of tumors that developed at multiple sites following intracardiac injection of Her2/neu positive, trastuzumab-insensitive JIMT-1 cells [1].